Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-24

Clinical Trial Update: Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating enzastaurin with bevacizumab in recurrent glioblastoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-24